Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / BMRN
Stock rating
BioMarin Pharmaceuticals Inc (BMRN) Stock Rating & Analysis
As of September 25, 2026, MELANY rates BioMarin Pharmaceuticals Inc 60 out of 100 (Promising). Its highest factor score is analyst sentiment at 80, and its lowest is earnings track record at 31.
MELANY ratingRated 2026-09-25BMRN · composite score
Why BMRN scores 60/100
BMRN's 8 factor scores run from 31 to 80, and 2 of them sit above its composite of 60. Here is how BMRN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 31.7x, earnings growth accelerating
- PEG ratio 0.36 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 51%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Analyst targets 52% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BMRN compares
As of October 7, 2026, BioMarin Pharmaceuticals Inc is tied for 15th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for BMRN
- Trailing P/E 159x, priced for sustained growth, any miss could de-rate hard
Sector and theme context
BioMarin Pharmaceuticals Inc sits in the Healthcare sector theme, which MELANY currently rates 44/100 for strength. Theme strength feeds BMRN's momentum and catalyst factors above.
BMRN trade plan (Pro)
MELANY has a full position plan for BioMarin Pharmaceuticals Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BMRN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. BioMarin Pharmaceuticals Inc's 60/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BMRN
Is BioMarin Pharmaceuticals Inc (BMRN) a buy?
As of 2026-09-25, MELANY rated BioMarin Pharmaceuticals Inc Promising with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is BioMarin Pharmaceuticals Inc's MELANY score?
BioMarin Pharmaceuticals Inc (BMRN) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BMRN stock rating calculated?
MELANY scores BMRN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy BioMarin Pharmaceuticals Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates BioMarin Pharmaceuticals Inc (BMRN) Promising with a composite of 60/100 as of 2026-09-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BMRN stock price forecast?
MELANY does not publish price targets or forecasts for BMRN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for BioMarin Pharmaceuticals Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BMRN stock overvalued or undervalued?
MELANY's valuation factor currently reads 55/100 for BioMarin Pharmaceuticals Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BMRN's read.
What price should I buy BMRN at?
Rather than chasing the current price, MELANY computes a smart entry zone for BMRN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BMRN stock?
The top risks MELANY currently flags for BioMarin Pharmaceuticals Inc: Trailing P/E 159x, priced for sustained growth, any miss could de-rate hard. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is BioMarin Pharmaceuticals Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 54/100 for BioMarin Pharmaceuticals Inc, and earnings track record, at 31/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BMRN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 61/100 for BMRN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BMRN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BMRN continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BMRN included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.